Global Private Equity Giants Target Indian Pharma Asset

Brookfield Asset Management and Sweden’s EQT Group are reportedly in advanced negotiations to acquire Fosun Pharma’s majority stake in Gland Pharma, an India-based injectable drug manufacturer. The deal, if concluded, could be worth around $3 billion, making it one of the largest pharma buyouts in India in recent years.

Fosun Eyes Exit Amid China Strategy Shift

Fosun Pharma, the Chinese parent of Gland Pharma, is exploring a full exit as part of its broader strategy to reduce leverage and rebalance international exposure. The company currently holds a majority stake of around 57.86% in Gland Pharma, which it acquired in 2017 for $1.1 billion.

Why Gland Pharma Is Attractive

Gland Pharma is known for its strong U.S. FDA compliance, robust injectable portfolio, and deep presence in the U.S. and EU markets. With end-to-end manufacturing facilities, the company has emerged as a reliable outsourcing partner for global drugmakers, especially in complex injectable therapies.

Strategic Fit for Brookfield and EQT

Brookfield and EQT are both deep-pocketed private equity firms actively looking to expand in India’s high-growth healthcare space. A deal would mark EQT’s entry into the Indian pharmaceutical segment, while Brookfield could significantly expand its healthcare vertical.

Valuation and Deal Mechanics Still Evolving

While the estimated deal size is around $3 billion, the final contours of the transaction are still being negotiated. Fosun’s original asking valuation was reportedly higher, but ongoing global market volatility and regulatory challenges have brought expectations closer to current levels.

Market Reaction and Road Ahead

Shares of Gland Pharma have shown modest volatility as the deal talks progressed. Investors appear cautiously optimistic, especially if the acquisition results in greater operational focus and global expansion. Regulatory approval both in India and abroad will be key before any formal announcement is made.

Final Word

If successful, the Brookfield-EQT bid would underscore the rising interest of global investors in Indian pharmaceutical assets, especially amid China+1 strategies and global supply chain realignments. The acquisition would also highlight Gland Pharma’s evolution from a niche Hyderabad-based company into a globally recognized injectable manufacturer.